KYS202002A

N/A

Report date: 2025/02/26 13:21:41

Base Information

Drug NameKYS202002A
Drug Alias NameKYS202002AKYS-202002A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionLymphocyte differentiation antigen CD38 inhibitors
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsLupus Erythematosus, SystemicMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Kanion Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesIntellective Suzhou Co LtdJiangsu Kanion Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A